TransMedics Group, Inc. $TMDX Shares Purchased by Odyssean LLC

Odyssean LLC grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 191.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,814 shares of the company’s stock after acquiring an additional 8,424 shares during the quarter. Odyssean LLC’s holdings in TransMedics Group were worth $851,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Royal Bank of Canada lifted its position in TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after purchasing an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares during the last quarter. Goldman Sachs Group Inc. grew its position in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares during the period. Finally, M&T Bank Corp acquired a new stake in shares of TransMedics Group in the second quarter valued at approximately $209,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Down 1.5%

TMDX stock opened at $92.22 on Thursday. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of 23.71 and a beta of 1.90. The firm’s 50-day moving average is $78.59 and its two-hundred day moving average is $94.23. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same quarter last year, the business earned $0.92 earnings per share. The company’s revenue was up 20.7% on a year-over-year basis. On average, analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TMDX. Weiss Ratings downgraded TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Stifel Nicolaus raised their target price on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $124.00 target price on shares of TransMedics Group in a research note on Tuesday, June 30th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Finally, UBS Group reduced their price target on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and a consensus target price of $124.18.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.